Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03186339
Other study ID # IPPM2017TASQ
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 8, 2017
Est. completion date January 13, 2020

Study information

Verified date May 2022
Source Institut für Pharmakologie und Präventive Medizin
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective, multi-centre, multi-national registry with a follow-up of 3 months, in five European countries and Canada (Toronto), with elective patients undergoing TF-TAVI (n=120) and isolated SAVR (n=120), respectively and a control group of 50 patients receiving medical treatment only. All patient groups will fill in three different questionnaires to assess quality of life in 5 different languages (English, French, German, Italian and Spanish). One of these will be a new questionnaire, the Toronto Aortic Stenosis QoL (Quality of Life) questionnaire (TASQ).


Description:

Currently, there are two cardiovascular disease QoL scales which have been used in studies of patients with aortic stenosis - the Minnesota Living with Heart Failure (MLHF) questionnaire and the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ has now become the only cited health related (HR) QoL validated scale for use among a growing TAVI (Transcatheter Aortic Valve Implantation) patient population; however questions on the KCCQ do not reflect the concerns and lifestyle of patients proceeding for aortic valve intervention. Many of the questions do not reflect this patient population's perspective of well-being in contrast to perceptions by the general cardiac population on which it was validated. It is important to capture the disruptions caused by a chronic disease and its treatment on lifestyles, activities, and interests; that is interference with psychologically meaningful activity. It has been noted that this interference varies by disease process and treatment by general scales such as the Illness Intrusiveness Scale . Due to issues of limited validity of the KCCQ for TAVI / SAVR (Surgical Aortic Valve Replacement) patients related to symptom items not being revised from their original use for congestive heart failure, a new original HR-QoL questionnaire was proposed: The "Toronto Aortic Stenosis Quality of Life Questionnaire" (TASQ) is a health specific measurement tool designed to measure changes in quality of life in aortic stenosis patients. The aim of this study is to validate this questionnaire in this specific patient population.


Recruitment information / eligibility

Status Completed
Enrollment 272
Est. completion date January 13, 2020
Est. primary completion date August 15, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - severe aortic stenosis - age > 18 years - in case of TAVI or SAVR: intention to treat the AS employing an Edwards valve Exclusion Criteria: - patients not providing informed consent - patients with major cognitive impairment - emergency patients

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
TAVI
transfemoral transcatheter aortic valve implantation
SAVR
isolated surgical valve replacement
Other:
MM
management of aortic stenosis by medical treatment only

Locations

Country Name City State
Austria Medical University of Innsbruck Innsbruck
Canada University Health Network, Toronto General Hospital Toronto Ontario
France Hospital Jacques Cartier Massy
France Bichat Hospital - Claude-Bernard Paris
Germany UKSH University Clinical Center Schleswig-Holstein Kiel Schleswig-Holstein
Italy Structual Interventional Cardiology, University Hospital Careggi Florence
Italy Department of Medicine, University of Verona Verona
Spain University Hospital Vall d'Hebron Barcelona
Spain Hospital Juan Canalejo Coruna Coruna
United Kingdom Barts Heart Centre London

Sponsors (2)

Lead Sponsor Collaborator
Institut für Pharmakologie und Präventive Medizin Edwards Lifesciences

Countries where clinical trial is conducted

Austria,  Canada,  France,  Germany,  Italy,  Spain,  United Kingdom, 

References & Publications (3)

Frank D, Kennon S, Bonaros N, Romano M, Lefèvre T, Di Mario C, Stefàno P, Ribichini FL, Himbert D, Urena-Alcazar M, Salgado-Fernandez J, Cuenca Castillo JJ, Garcia B, Kurucova J, Thoenes M, Lüske C, Bramlage P, Styra R. Trial protocol for the validation of the 'Toronto Aortic Stenosis Quality of Life (TASQ) Questionnaire' in patients undergoing surgical aortic valve replacement (SAVR) or transfemoral (TF) transcatheter aortic valve implantation (TAVI): the TASQ registry. Open Heart. 2019 May 21;6(1):e001008. doi: 10.1136/openhrt-2019-001008. eCollection 2019. — View Citation

Frank D, Kennon S, Bonaros N, Stastny L, Romano M, Lefèvre T, Di Mario C, Stefàno P, Ribichini F, Himbert D, Urena-Alcazar M, Salgado-Fernandez J, Castillo JJC, Garcia Del Blanco B, Deutsch C, Sykorova L, Kurucova J, Thoenes M, Lüske CM, Bramlage P, Styra — View Citation

Kennon S, Styra R, Bonaros N, Stastny L, Romano M, Lefèvre T, Di Mario C, Stefàno P, Ribichini FL, Himbert D, Urena-Alcazar M, Salgado-Fernandez J, Cuenca Castillo JJ, Garcia B, Deutsch C, Sykorova L, Kurucova J, Thoenes M, Lüske C, Bramlage P, Frank D. Q — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in QoL as assessed by SF12 (Short Form 12) Questionnaire Change in quality of life as assessed by the SF12 using a points system 3 months from baseline examination
Primary Change in QoL as assessed by KCCQ (The Kansas City Cardiomyopathy Questionnaire) Change in quality of life as assessed by the KCCQ using a points system 3 months from baseline examination
Primary Change in QoL as assessed by TASQ (Toronto Aortic Stenosis Quality of Life Questionnaire) Change in quality of life as assessed by the TASQ using a points system 3 months from baseline examination
Secondary Difference in change in QoL between arms Difference in change in QoL between the three intervention arms 3 months from baseline examination
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Terminated NCT02854319 - REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System N/A
Recruiting NCT05601453 - The ReTAVI Prospective Observational Registry
Withdrawn NCT05481814 - CPX in Paradoxical Low Flow Aortic Stenosis
Completed NCT02241109 - Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity N/A
Completed NCT01700439 - Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve N/A
Recruiting NCT04429035 - SLOW-Slower Progress of caLcificatiOn With Vitamin K2 N/A
Completed NCT04103931 - Impact of a Patient Decision Aid for Treatment of Aortic Stenosis N/A
Completed NCT03950440 - Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
Active, not recruiting NCT02661451 - Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) N/A
Completed NCT02758964 - Evaluation of Cerebral Thrombembolism After TAVR
Completed NCT02847546 - Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation N/A
Completed NCT02792452 - Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
Not yet recruiting NCT02541877 - Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve Phase 3
Not yet recruiting NCT02536703 - Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population Phase 3
Active, not recruiting NCT02249000 - BIOVALVE - I / II Clincial Investigation N/A
Not yet recruiting NCT02221921 - Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI N/A
Active, not recruiting NCT02080299 - Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation Phase 2
Terminated NCT01939678 - Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
Recruiting NCT01683474 - Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis N/A